文献速递血液透析通路

头静脉弓狭窄在头臂型动静脉瘘患者中的治疗策略

Treatment Strategies for Cephalic Arch Stenosis in Patients with Brachiocephalic Arteriovenous Fistula.
PubMed 文献 · Ann Vasc Surg · 2018-07-26

该回顾性研究纳入2011年1月至2016年6月462例头臂型动静脉瘘(BCAVF)患者,头静脉弓狭窄(CAS)发生率为16.7%(77例),其中54.5%(42例)因临床显著CAS接受治疗。初次治疗中经皮腔内球囊血管成形术(PTA)36例(85.7%),头静脉移位术(CVT)6例(14.3%),另有9例PTA后行CVT,CVT总计15例。CVT在6、12个月的一期辅助通畅率(100.0%、87.5%)和二期通畅率(100%、100%)均优于PTA(57.3%、56.9%),再干预率更低。

要点

  • BCAVF患者CAS发生率为16.7%,其中54.5%因临床显著CAS需治疗。
  • CVT组6、12个月一期辅助通畅率100.0%、87.5%,PTA组68.2%、57.3%(P=0.038)。
  • CVT组6、12个月二期通畅率均为100%,PTA组72.0%、56.9%(P=0.010)。

核心结论

  • CAS是BCAVF功能障碍的常见原因,需要仔细监测。
  • 作者认为,为获得更好的长期通畅率和更少的再干预,CAS的治疗应考虑CVT。

研究设计与样本

  • 回顾性研究,2011年1月至2016年6月共462例患者接受BCAVF创建。
  • CAS定义为超声上头静脉与腋静脉汇合处狭窄>50%。
  • 临床显著CAS定义为流量较前次检查下降>25%、静脉压升高、穿刺点止血延迟和/或急性血栓性闭塞。

主要发现

  • 77例(16.7%)患者发生CAS,其中42例(54.5%)因临床显著CAS接受治疗。
  • 初次治疗:PTA 36例(85.7%),CVT 6例(14.3%);9例PTA后行CVT,CVT总计15例。
  • 6、12个月一期辅助通畅率:PTA组68.2%、57.3%,CVT组100.0%、87.5%(P=0.038)。
  • 6、12个月二期通畅率:PTA组72.0%、56.9%,CVT组100%、100%(P=0.010)。
  • 中位干预率:PTA组2.5次/通路年,CVT组1.5次/通路年。

关键数值与推荐

  • CAS超声诊断标准:头静脉与腋静脉汇合处狭窄>50%。
  • 临床显著CAS标准:流量较前次检查下降>25%、静脉压升高、穿刺点止血延迟和/或急性血栓性闭塞。

临床怎么用

  • 作者认为,CAS是BCAVF功能障碍的常见原因,需要仔细监测。
  • 作者建议,CAS的治疗应考虑CVT,以获得更好的长期通畅率和更少的再干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cephalic arch is one of the sites most susceptible to stenosis in brachiocephalic arteriovenous fistula (BCAVF). We performed a retrospective study to identify the incidence of cephalic arch stenosis (CAS) in BCAVF, to compare the patency of percutaneous transluminal balloon angioplasty (PTA) with that of cephalic vein transposition (CVT), and to establish the optimal treatment strategy for CAS. METHODS: Between January 2011 and June 2016, 462 patients underwent BCAVF creation. CAS was defined as >50% stenosis at the confluence of the cephalic and axillary veins on ultrasonography. Treatment was planned for clinically significant CAS, which was defined as >25% reduction in flow volume compared to previous examination, elevation of venous pressure, delayed puncture site hemostasis, and/or acute thrombotic occlusion. RESULTS: Seventy-seven (16.7%) patients had CAS and 42 of them (54.5%) were treated for clinically significant CAS. PTA was performed in 36 patients (85.7%), and CVT was done in 6 patients (14.3%) as the initial treatment. Nine patients underwent CVT after PTA, resulting in a total of 15 patients treated with CVT. Investigation of the patency of the 36 cases of PTA and 15 cases of CVT revealed that primary-assisted patency rates at 6 and 12 months were 68.2% and 57.3% for PTA and 100.0% and 87.5% for CVT, respectively (P = 0.038). Secondary patency rates at 6 and 12 months were 72.0% and 56.9% for PTA and 100% and 100% for CVT, respectively (P = 0.010). The median intervention rate was 2.5 interventions per access-year in the 36 cases treated with PTA and 1.5 interventions per access-year in the 15 cases treated with CVT. CONCLUSIONS: CAS is a common cause of BCAVF dysfunction, and careful surveillance is warranted. CVT should be considered for treatment of CAS to achieve better long-term patency with fewer reinterventions.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim SM, Yoon KW, Woo SY, et al. Treatment Strategies for Cephalic Arch Stenosis in Patients with Brachiocephalic Arteriovenous Fistula. Ann Vasc Surg. 2018. PMID: 30055242. doi:10.1016/j.avsg.2018.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。